Histopathologic and Molecular Insights Following the Management of Ameloblastomas via Targeted Therapies – Pathological and Clinical Perspectives
Sign Up to like & getrecommendations! Published in 2024 at "Head and Neck Pathology"
DOI: 10.1007/s12105-024-01734-2
Abstract: Current standard of care for ameloblastoma (conventional/unicystic - mural type) usually mandates extensive bone resection that frequently necessitates immediate reconstruction with serious sequelae, especially among young patients. BRAF-mutated ameloblastomas can be targeted by BRAF inhibitors… read more here.
Keywords: treatment; residual tumor; response; partial response ... See more keywords
Partial Response and Stable Disease Correlate with Positive Outcomes in Atezolizumab-treated Patients with Advanced Urinary Tract Carcinoma.
Sign Up to like & getrecommendations! Published in 2020 at "European urology focus"
DOI: 10.1016/j.euf.2020.10.009
Abstract: BACKGROUND The value of a complete response to immune checkpoint inhibitor treatment for urothelial cancer is well recognised, but less is known about long-term outcomes in patients with a partial response or the benefit of… read more here.
Keywords: atezolizumab treated; partial response; response; treated patients ... See more keywords
Prevalence and predictors of proton pump inhibitor partial response in gastroesophageal reflux disease in systemic sclerosis: a prospective study
Sign Up to like & getrecommendations! Published in 2020 at "Scientific Reports"
DOI: 10.1038/s41598-020-57636-0
Abstract: Proton pump inhibitor (PPI) twice daily dosing is a standard therapy for gastroesophageal reflux disease (GERD) in systemic sclerosis (SSc) but there is no data on its response rate or the predictors of PPI-partial response… read more here.
Keywords: ssc; partial response; response; response gerd ... See more keywords
Partial Response to Naxitamab for Brain Metastasis in Neuroblastoma
Sign Up to like & getrecommendations! Published in 2024 at "Journal of Pediatric Hematology/Oncology"
DOI: 10.1097/mph.0000000000002807
Abstract: Neuroblastoma (NBL) is a common pediatric tumor arising from sympathetic ganglion cells. High-risk NBL is based on age, stage, histology, and MYCN amplification, and is associated with a high mortality rate. The combination of naxitamab… read more here.
Keywords: response naxitamab; brain; high risk; partial response ... See more keywords
Estimation of Modulation Index for Partial Response CPM Signal
Sign Up to like & getrecommendations! Published in 2018 at "IEEE Access"
DOI: 10.1109/access.2018.2794959
Abstract: Continuous phase modulation (CPM) is a power and bandwidth efficient modulation scheme used in cellular, personal, and satellite communications among other applications. If the modulation index of the CPM waveform used by the transmitter is… read more here.
Keywords: modulation; modulation index; partial response; cpm signal ... See more keywords
PR-NN: RNN-Based Detection for Coded Partial-Response Channels
Sign Up to like & getrecommendations! Published in 2021 at "IEEE Journal on Selected Areas in Communications"
DOI: 10.1109/jsac.2020.3041377
Abstract: In this paper, we investigate the use of recurrent neural network (RNN)-based detection of magnetic recording channels with inter-symbol interference (ISI). We refer to the proposed detection method, which is intended for recording channels with… read more here.
Keywords: performance; partial response; rnn based; based detection ... See more keywords
Opposite Partial Response Filter for Shingled Magnetic Recording Systems
Sign Up to like & getrecommendations! Published in 2020 at "IEEE Magnetics Letters"
DOI: 10.1109/lmag.2020.3004298
Abstract: Shingled magnetic recording (SMR) is regarded as the most influential technology for the next-generation magnetic recording systems. The SMR tracks are partly overlapped by each other, and the SMR systems can obtain higher area densities… read more here.
Keywords: response filter; magnetic recording; opposite partial; partial response ... See more keywords
Partial response to dabrafenib and trametinib in relapsed BRAF V600E-Mutated multiple myeloma and possible mechanisms of resistance
Sign Up to like & getrecommendations! Published in 2022 at "BMJ Case Reports"
DOI: 10.1136/bcr-2021-246264
Abstract: BRAF V600E mutations are detected in 3%–10% of patients with multiple myeloma (MM) and are associated with more aggressive disease, higher frequency of extramedullary growth and shorter survival. Monotherapy with the BRAF inhibitor vemurafenib has… read more here.
Keywords: braf; braf v600e; partial response; multiple myeloma ... See more keywords
Giant Cell Temporal Arteritis Followed by Severe Encephalopathy Induced by Immunotherapy in a Patient with Metastatic Renal Cell Carcinoma Achieving Durable Partial Response: A Case Report
Sign Up to like & getrecommendations! Published in 2024 at "Case Reports in Oncology"
DOI: 10.1159/000540660
Abstract: Abstract Introduction Combined immuno-oncology (IO) regimens are the cornerstone of the current front-line systemic therapy for metastatic renal cell carcinoma (mRCC). Despite the fact that combined IO regimens show high efficacy, they are often accompanied… read more here.
Keywords: oncology; durable partial; cell; partial response ... See more keywords
Partial response of pulmonary adenocarcinoma with symptomatic brain metastasis to nivolumab plus high-dose oral corticosteroid: a case report
Sign Up to like & getrecommendations! Published in 2017 at "Journal of Medical Case Reports"
DOI: 10.1186/s13256-017-1334-z
Abstract: BackgroundNivolumab, a monoclonal antibody targeting the programmed death-1 receptor, is indicated in locally advanced or metastatic non-small cell lung cancer, with progression after platinum-based chemotherapy. Up-to-now, few data are available concerning brain activity of this… read more here.
Keywords: corticosteroid; partial response; high dose; case ... See more keywords
Clinical Outcomes and Histologic Findings of Patients With Hepatocellular Carcinoma With Durable Partial Response or Durable Stable Disease After Receiving Atezolizumab Plus Bevacizumab
Sign Up to like & getrecommendations! Published in 2024 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.24.00645
Abstract: PURPOSE Durable partial response (PR) and durable stable disease (SD) are often seen in patients with hepatocellular carcinoma (HCC) receiving atezolizumab plus bevacizumab (atezo-bev). This study investigates the outcome of these patients and the histopathology… read more here.
Keywords: durable partial; durable stable; response durable; atezo bev ... See more keywords